Small pharma stock price rocketed 48% on Monday

[ginfreely]

https://www.nasdaq.com/articles/heres-why-cytokinetics-is-rocketing-higher-today-2021-07-19

Here's Why Cytokinetics Is Rocketing Higher Today​

CONTRIBUTOR
Cory Renauer The Motley Fool
PUBLISHED
JUL 19, 2021 12:28PM EDT

 

[ginfreely]

Shares of Cytokinetics (NASDAQ: CYTK)are up 48.4% as of 12:00 p.m. EDT on Monday. Investors were caught off guard by some encouraging results from a clinical trial with CK-274, a potential new treatment for hypertrophic cardiomyopathy (HCM).

So what​

Patients with HCM have heart muscle that becomes thicker, which can cause it to pump with too much force. Today, Cytokinetics showed us clear signs that CK-274, an oral cardiac myosin inhibitor, can safely get the hearts of HCM patients to relax.

Image source: Getty Images.

Treatment with a low dose of CK-274 lowered 14 patients' left ventricular outflow tract pressure gradient (LVOT-G) from an average of 53.8 millimeters of mercury (mmHg) to just 13.4 mmHg after 10 weeks. Among 14 patients who received a higher dosage, LVOT-G scores improved by a slightly wider margin that worked out to 43.1 mmHg. Scores for the placebo group also improved, but only by 8.1 mmHg.

Now what​

Unfortunately for Cytokinetics, CK-274 isn't the only cardiac myosin inhibitor out there. In 2020, Bristol Myers Squibb (NYSE: BMY) splashed out with a $13.1 billion acquisition of Myokardia to access a similar drug called mavacamten. The FDA began reviewing an application to treat HCM patients with mavacamten in March, and an approval decision is expected on Jan. 28, 2022.

 

[ginfreely]

It's still early, but it looks as if Cytokinetics' drug has the upper hand. During the pivotal study supporting mavacamten's application, just 74% of patients treated had LVOT-G levels that fell to target levels. Treatment with CK-274 helped a surprising 92.9% of patients in the high-dosage cohort of Cytokinetics' study hit their target.

 

[ginfreely]

Investors buying up shares of Cytokinetics on today's news have a lot to look forward to. Cytokinetics expects to begin a phase 3 trial with CK-274 before the end of the year. Also in 2021, the company expects to send the FDA a new drug application for its lead candidate, omecamtiv mecarbil.

 

[ginfreely]

https://www.statnews.com/2021/07/19...atients-with-inherited-form-of-heart-disease/​

Cytokinetics drug improves blood flow in patients with inherited form of heart disease​

• 

By Adam Feuerstein July 19, 2021

ADOBE

Cytokinetics said Monday that its experimental drug demonstrated statistically significant improvements in blood flow for patients with an inherited form of heart disease — a result that compares favorably to a competing heart drug recently acquired by Bristol Myers Squibb.

In a small, mid-stage clinical trial, 13 of 14 patients, or 93%, treated with a higher dose of the Cytokinetics drug, called CK-274, achieved improvement in blood flow to a target level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM. No concerning or unexpected side effects were reported.

 

[ginfreely]

https://finance.yahoo.com/news/cytokinetics-announces-proposed-public-offering-200000872.html

Cytokinetics Announces Proposed Public Offering of Common Stock​

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Mizuho Securities and JMP Securities are acting as passive book-runners.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a prospectus) filed on November 6, 2019 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone: 1-866-803-9204, or by email at [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected].

 

[ginfreely]

https://finance.yahoo.com/news/cytokinetics-announces-proposed-public-offering-200000872.html

Cytokinetics Announces Proposed Public Offering of Common Stock​

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Mizuho Securities and JMP Securities are acting as passive book-runners.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a prospectus) filed on November 6, 2019 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone: 1-866-803-9204, or by email at [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected].

Looks like it’s standard procedure for Angmoh the best small pharma to issue more stocks after any good news.

 

[ginfreely]

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activatorsand muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

https://en.wikipedia.org/wiki/Cytokinetics

 

[ginfreely]

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF.[4]Operations began in 1998.

Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins.[4] Eventually, the company narrowed its focus to the mechanics of muscle biology.[4] Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients suffering from cardiovascular and neuromuscular diseases.[5][6] The company’s lead muscle activator development program is for a drug called omecamtiv mecarbil, currently being studied for the potential treatment of heart failure.[4] Additional drugs include reldesemtiv, a next-generation fast skeletal muscle troponin activator, and CK-274, a small-molecule myosin inhibitor.[7][8]

 

[ginfreely]

In 2004 the company completed its initial public offering(IPO).[9]

Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times.[4] In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021 and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil. [10][11]

In January 2007, Cytokinetics named Robert I. Blum as President and CEO.[12] Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.[13]

In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.[14]

In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, CK-274, in China and certain neighboring regions.[15]

 

[ginfreely]

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF.[4]Operations began in 1998.

Angmoh the best do good for humanity not like asian turtle sons of whores human cockroaches @glockman and clones @Cottonmouth @sweetiepie @plzhelpme etc that proudly take bto handouts paid by me taxpayers and then hide in forum as turtle criminals to viciously attack me

 

[ginfreely]

Angmoh the best do good for humanity not like asian turtle sons of whores human cockroaches @glockman and clones @Cottonmouth @sweetiepie @plzhelpme etc that proudly take bto handouts paid by me taxpayers and then hide in forum as turtle criminals to viciously attack me

Or other shameless useless Asian turtle sons of whores that proudly hide in unit to make loud knocks on my windows or their floor to harass me in the wee hours

 

[ginfreely]

Or other shameless useless Asian turtle sons of whores that proudly hide in unit to make loud knocks on my windows or their floor to harass me in the wee hours

Aided by hypocrite Asian bitches that cry metoo while no qualms to gang up with their man to viciously attack woman